quick detail:
cas no.: |
936563-96-1 |
other names: |
ibrutinib |
mf: |
ibrutinib |
einecs no.: |
936563-96-1 |
place of origin: |
shanxi , china (mainland) |
type: |
antineoplastic agents |
grade standard: |
medicine grade |
brand name: |
wango |
model number: |
ibrutinib 936563-96-1 |
purity: |
98% ibrutinib |
chemical name: |
ibrutinib |
appearance: |
white solid |
identification: |
should conform |
composition test: |
should conform |
ph: |
6.5~7.5 |
loss on drying: |
nmt5.0% |
usage: |
antineoplastics |
specification:
test |
specification |
result |
appearance |
white to off-white solid |
off-white solid |
identification by nmr |
to match with the reference standard |
conforms |
purity |
≥99.0% |
99.5% |
total impurities |
≤1.0% |
0.5% |
single impurity |
≤0.2% |
0.2% |
chiral purity |
≥99.0% |
99.5% |
kf |
≤1.0% |
0.5% |
solvent |
mtbe≤3000ppm thf≤72ppm methyl alcohol≤3000ppm ea:≤5000ppm 2-me-thf≤720ppm methylbenzene≤400ppm |
conforms |
conclusion |
complies with in-house standard. |
function :
ibrutinib is a cancer drug that targets b-cell malignancies such as certain leukemias and lymphomas.